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CCR5 expression determines susceptibility to infection, cell tropism, and the rate of human immunodefi-
ciency virus type 1 (HIV-1) disease progression. CCR5 is also considered the major HIV-2 coreceptor in vivo,
in spite of broad coreceptor use in vitro. Here we report a significantly increased proportion of memory-effector
CD4 T cells expressing CCR5 in HIV-2-infected patients correlating with CD4 depletion. Moreover, HIV-2
proviral DNA was essentially restricted to memory-effector CD4, suggesting that this is the main target for
HIV-2. Similar levels of proviral DNA were found in the two infection categories. Thus, the reduced viremia and
slow rate of CD4 decline that characterize HIV-2 infection seem to be unrelated to coreceptor availability.
Human immunodeficiency virus type 2 (HIV-2) immunode-
ficiency is characterized by slow disease progression with lim-
ited impact on the survival of the majority of infected adults
(20, 33, 45). The rate of CD4 T-cell decline is much slower in
HIV-2 than in HIV-1 disease, and there is a low plasma viral
load irrespective of disease stage (2, 4, 9, 17, 20, 32, 41, 43).
The factors contributing to the suggested decreased rate of
virus production in HIV-2 infection remain largely unknown.
In spite of the promiscuity of coreceptor usage exhibited by
HIV-2 in in vitro experimental settings (8, 13, 16, 22, 29, 39,
40), several lines of evidence show that CCR5 and CXCR4 are
the major coreceptors for HIV-2 infection in vivo (6, 24, 25).
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TABLE 1. Cohort characterization
Characteristic
Value for group
Healthy controls HIV-2-positive patientsc HIV-1-positive patientsc
No. of subjects (no. male/no. female) 21 (9/12) 22 (6/16) 23 (10/13)
Age (yr)a 42  4 (21–84) 46  3 (21–64) 37  3 (20–68)
Ethnicity
White 17 8 13
Other 4 14 10
HIV transmission category
Heterosexual n.a.b 17 18
Homosexual or bisexual n.a. 1 3
Intravenous drug user n.a. 1 2
Blood transfusion n.a. 3 0
CD3 count in cells/la 1,844  165 (767–3,488) 1,305  119 (427–2,629)* 1,454  158 (378–3,554)*
% CD3a 73  1.8 (58–84) 71  2.3 (48–87) 74  1.9 (55–90)
CD4 count (cells/l)a 1,174  108 (581–2,387) 551  73 (38–1,207)*** 498  61 (86–1,300)***
% CD4a 46  1.8 (33–64) 29  2.8 (4–49)*** 28  2.4 (9–52)***
CD8 count (cells/l)a 632  71 (234–1,236) 729  76 (180–1,456) 861  100 (269–2,007)
% CD8a 24  1.5 (13–38) 40  2.9 (24–70)*** 44  2.4 (28–64)***
Viremia (RNA; no. of copies/ml)a n.a. 409  190 (200–4,006)d 75,508  30,429 (118–548,631)e
Proviral DNA (copies/106 PBMC)a n.a. 1,760  823 (5–10,725)f 2,481  863 (61–12,565)f
a Data are means  standard errors of the means with limits in brackets.
b n.a., not applicable.
c Significance in comparison with healthy control results is represented as follows: *, P  0.05; ***, P  0.0001. There were no significant differences between the
HIV-2 and HIV-1 cohorts except for the viremia results (P  0.0001).
d HIV-2 viremia was quantified by a reverse transcriptase PCR-based test (41); the results were below 200 RNA copies/ml (cutoff) for 19 out of the 21 patients studied.
In these cases the cutoff value was used.
e HIV-1 viremia was quantified by reverse transcriptase PCR (Ultrasensitive Test; Roche Molecular Systems, Branchburg, NJ). The cutoff was 50 RNA copies/ml.
f Proviral DNA was quantified by real-time PCR and was detected in all 17 HIV-2-infected patients and all 16 HIV-1-infected patients investigated.
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In HIV-1-infected patients, CCR5 expression determines
susceptibility to infection, cell tropism, and the rate of disease
progression and is currently an important target of new anti-
retroviral drugs (10, 11, 21, 27, 34, 35).
There are scanty data available on CCR5 and CXCR4 ex-
pression in HIV-2-infected patients. A previous study of a
Senegalese cohort reported lower CCR5 expression in HIV-2
than in HIV-1 infection, but as these patients, unlike our co-
horts, were not stratified according to CD4 depletion or vire-
mia, direct comparison is problematic (38).
We analyzed here CCR5 and CXCR4 expression in freshly
isolated peripheral blood mononuclear cells (PBMC) from
untreated HIV-2- and HIV-1-infected subjects who were cur-
rently living in Portugal and attending outpatient clinics in
Lisbon and who exhibited no known ongoing opportunistic
infections or tumors. The epidemiological and clinical features
FIG. 1. CCR5 and CXCR4 expression in circulating CD4 T cells from HIV-2- and HIV-1-infected patients as well as healthy controls. Freshly
isolated PBMC were surface stained with anti-CCR5 (clone 2D7) or anti-CXCR4 (clone 12G5) monoclonal antibodies (phycoerythrin conjugated;
BD Biosciences, San Jose, CA), acquired, and analyzed in a FACSCalibur flow cytometer using CellQuest software (BD Biosciences). Percentages
of CCR5- and CXCR4-expressing cells within total CD4 T cells (CD4), a naı¨ve CD4 subset (CD4 CD45RA), and a memory CD4 subset (CD4
CD45RAneg) are shown in panels A and C, respectively. Bars represent means  standard errors of the means. Representative contour plots of
the flow cytometric analysis of CD4 gated T cells of an HIV-2-infected patient with 291 CD4 T cells/l are illustrated in panel B. (D) Correlation
between the percentage of CCR5 cells within the CD4 subset and the frequency of circulating CD4 T cells. Each dot represents one individual.
The Pearson correlation coefficients for the different cohorts are shown. The median fluorescence intensities (MedianFI) of the whole population
of CCR5- and CXCR4-expressing CD4 T cells are shown in panels E and F, respectively. Each dot represents one individual; bars represent
means. Statistical analysis was performed using GraphPad Prism version 4.00 (GraphPad Software, San Diego, CA). The data were compared using
an unpaired t test. Spearman’s correlation coefficients were used to determine the correlations between two variables. P values  0.05 were
considered significant and are depicted in the figure.
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of these cohorts, as well as of healthy controls, are summarized
in Table 1. Of note, HIV-2 and HIV-1 cohorts exhibited sim-
ilar levels of CD4 depletion but striking differences in viremia.
CCR5 and CXCR4 expression were assessed by flow cytom-
etry in freshly isolated PBMC as previously described (42).
HIV-2-positive patients exhibited a higher frequency of
CCR5 cells within the CD4 subset that reaches statistical
significance than that seen with healthy subjects (Fig. 1A). In
HIV-2 patients CCR5 expression was also largely confined to
the memory CD4 CD45RA population, as illustrated in the
representative contour plot of Fig. 1B.
The frequencies of CXCR4 cells within CD4 T cells
showed no significant differences among the three cohorts,
although there was a trend to lower frequencies in the HIV-2
cohort in both the naı¨ve and memory subsets (Fig. 1C).
A significant correlation between the frequency of CCR5
cells within the CD4 subset and the degree of CD4 depletion
was observed with the HIV-2 cohort that was not observed with
HIV-1-positive patients (Fig. 1D).
We have previously shown that CD4 depletion is directly
linked to immune activation in both HIV-2 and HIV-1 infec-
tions in spite of the striking differences in viremia (15, 42).
Since CCR5 is up-regulated upon T-cell activation, we looked
for a possible correlation between the frequency of CCR5
cells and the expression of HLA-DR, a marker widely used to
quantify immune activation in HIV disease (15). A significant
correlation was observed with the HIV-2 cohort (r  0.68; P 
0.0009) that was not found with HIV-1-positive patients (r 
0.25; P  0.2814).
These data illustrated the link between the expansion of
CCR5 cells and immune activation in HIV-2 infection. The
lower frequency of circulating CCR5 cells in HIV-1 infection
compared to HIV-2 results despite the similarities in height-
ened immune activation may be related to a continuous deple-
tion of the CCR5 pool in association with the high level of
viremia (19, 23).
The frequency of CCR5 cells may be underestimated
due to binding-induced receptor internalization (26, 30). In
fact, the assessment of the median fluorescence intensity
(MedianFI) of CCR5 CD4 T cells revealed similar and
significant down-regulation results for both HIV-2- and HIV-
1-infected cohorts in comparison with the results seen with
healthy subjects (Fig. 1E). This contrasts with the absence of
differences in MedianFI of CXCR4 CD4 T cells for the
three cohorts (Fig. 1F). It is noteworthy that HIV-2 infection
has been associated with high levels of production of RANTES,
MIP-1, and MIP-1 (1, 18, 28), possibly contributing to the
CCR5 down-regulation.
In order to exclude the possibility that CCR5	32 mutations
contribute to the low MedianFI of CCR5 (44), we screened the
cohorts for the presence of this allele using the primers de-
scribed in Table 2. None of the HIV-2- or HIV-1-infected
patients exhibited the CCR5	32 allele. There were five healthy
subjects heterozygous for CCR5	32. The exclusion of these
individuals from the analysis resulted in an even more signifi-
cant difference in the results of down-regulation of CCR5
MedianFI between HIV cohorts and healthy subjects (P 
0.0019 for HIV-2 and P  0.0001 for HIV-1).
On the other hand, despite differing levels of viremia, we did
not find significant differences between HIV-2 and HIV-1 pro-
viral DNA levels, suggesting the presence of similar numbers
of infected cells in the two infection categories (Table 1), in
agreement with previous reports (3–5, 14, 31). Proviral DNA
was assessed by absolute quantitative real-time PCR using an
ABI PRISM 7000 sequence detection system (Applied Biosys-
tems) with a detection range of 7 orders of magnitude and a
sensitivity of five copies. Reactions containing 150 ng of
genomic DNA extracted from 106 PBMC by use of an ABI
PRISM 6100 nucleic acid extractor (Applied Biosystems), 25
l of Platinum quantitative PCR SuperMix-UDG, 1 l ROX
reference dye (Invitrogen) (50
), 5 mM MgCl2, 300 nM
primer (each), and 200 nM probe (Table 2) were run in du-
plicate. Albumin was used to standardize DNA input.
It is worth noting that no correlation was found between the
TABLE 2. Primer and probe sequencesa
Primer or probe Sequenceb
HIV-2
Forward primer .......5-CGC GAG AAA CTC CGT CTT G-3
Reverse primer........5-CAC ACA ATA TGT TTT AGC CTG
TAC TTT TT-3
Probe ........................5-FAM-CCG GGC CGT AAC CT-MGB-3
HIV-1
Forward primer .......5-GGG AGA ATT AGA TCG ATG GGA
AA-3
Reverse primer........5-CTG CTT GCC CAT ACT ATA TGT
TTT AAT TTA-3
Probe ........................5-FAM-CCC TGG CCT TAA CCG AAT
T-MGB-3
Albumin
Forward primer .......5-TGC ATG AGA AAA CGC CAG TAA-3
Reverse primer........5-ATG GTC GCC TGT TCA CCA A-3
Probe ........................5-FAM-TCA CCA AAT GCT GCA CAG
A-MGB-3
CCR5c
Forward primer .......5-TTC ATT ACA CCT GCA GCT CT-3
Reverse primer........5-CAC AGC CCT GTG CCT CTT CTT
CTC ATT TCG-3
a Primers and probes were designed using Primer Express 2.0 software (Ap-
plied Biosystems, Foster City, CA) and checked against the Los Alamos HIV
database.
b FAM, 6-carboxyfluorescein; MGB, minor groove binding.
c Fifty nanograms of genomic DNA was amplified by PCR using 25 l of
Platinum PCR SuperMix (Invitrogen, Carlsbad, CA), 300 nM primer (each), and
5 mM MgCl2 and was run on a 2% agarose gel with DNA bands stained with
ethidium bromide.
TABLE 3. HIV-2 proviral DNA in CD4 naı¨ve and memory subsets
Case
No. of
copies of
proviral
DNA/106
PBMC
No. of
CD4
cells/l
Result for indicated subseta
CD4 memory CD4 naive
No. of
copies of
proviral
DNA/106
PBMC
% CCR5
No. of
copies of
proviral
DNA/106
PBMC
% CCR5
1 57 181 95 7.45 5 0.86
2 206 629 1,541 11.21 5 2.08
a Freshly isolated PBMC were successively gated using CD4 and CD45RA
(naı¨ve) or CD45RA (memory); the subsets were purified using FACSAria (BD
Biosciences), with purity higher than 98%.
VOL. 80, 2006 NOTES 12427
frequency of CCR5 cells within the CD4 subset and the levels
of HIV-2 proviral DNA (r  0.08; P  0.7483).
In order to evaluate the possibility that the similar levels of
proviral DNA in the presence of the dissimilar HIV-1 and
HIV-2 viremia results might be due to differences in cell tar-
gets, we purified the naı¨ve and the memory CD4 T cells from
PBMC of two HIV-2 patients with different levels of CD4
depletion by high-speed cell sorting using FACSAria (BD Bio-
sciences).
As depicted in Table 3, the levels of HIV-2 proviral DNA
documented in the naı¨ve subset were minimal. Therefore,
these data suggest that memory CD4 T cells are the main
targets for HIV-2 infection in vivo, reinforcing the idea of a
major role of CCR5 coreceptor in HIV-2 infection. This was in
agreement with data on HIV-1 infection in which integrated
proviruses are preferentially detected within the memory sub-
set (7, 12, 36).
In summary, HIV-2-infected patients showed an increase in
the proportion of CCR5 cells within the memory-effector
CD4 T cells in correlation with the degree of CD4 depletion
and immune activation. In contrast, in HIV-1 infection there
was dissociation between CCR5 and other markers of immune
activation which could be interpreted as an indirect evidence of
depletion of the CCR5 cells by HIV-1. However, the HIV-2
proviral load was also mainly restricted to memory-effector
CD4 T cells, suggesting these are the major HIV-2 targets,
which is consistent with CCR5 being the main HIV-2 corecep-
tor in vivo. Moreover, the levels of HIV-2 proviral load were
similar to those observed in untreated HIV-1-infected individ-
uals, suggesting equivalent numbers of infected cells resulting
from the two diseases in spite of viremia being undetectable in
the majority of the HIV-2 patients.
The presence of reduced HIV-2 viremia seems to be unre-
lated to coreceptor availability. Since HIV-2 is no less cyto-
pathic per se than HIV-1 (37), other host factors must be
implicated in the control of viral replication in spite of signif-
icant proviral DNA levels in HIV-2-positive patients. The fur-
ther investigation of the mechanisms contributing to this con-
trol of HIV-2 viremia in the absence of antiretroviral therapy
may prove to be useful in defining complementary therapeutic
strategies to control viral reservoirs in HIV-1.
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